Tags

Type your tag names separated by a space and hit enter

Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
Intern Med. 2016; 55(23):3453-3457.IM

Abstract

Hypercalcemia resulting in the elevation of serum parathyroid hormone-related protein (PTHrP) and suppression of serum PTH was observed in a patient with advanced cholangiocarcinoma (CCC) and multiple lymph node metastases. We confirmed humoral hypercalcemia of malignancy based on PTHrP-producing CCC. Chemotherapy with gemcitabine and cisplatin could not control the patient's serum PTHrP levels and the patient was affected with bisphosphonate-refractory hypercalcemia. We administered a single dose of denosumab, an anti-receptor activator of nuclear factor-kappaB ligand monoclonal antibody, and the patient's serum calcium levels remained close to the normal range for approximately 3 weeks without additional treatment.

Links

PMC Free PDF

Authors+Show Affiliations

Ashihara N
Department of Internal Medicine, Iida Municipal Hospital, Japan.
Nakajima K
No affiliation info available
Nakamura Y
No affiliation info available
Kobayashi M
No affiliation info available
Shirahata K
No affiliation info available
Maeda C
No affiliation info available
Uehara T
No affiliation info available
Gomi D
No affiliation info available
Ito N
No affiliation info available

MeSH

Bile Duct NeoplasmsBone Density Conservation AgentsCalciumCholangiocarcinomaDenosumabHumansHypercalcemiaMaleMiddle AgedParaneoplastic SyndromesParathyroid Hormone-Related ProteinProteins

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

27904108

Citation

Ashihara, Norihiro, et al. "Denosumab Is Effective for Controlling Serum Calcium Levels in Patients With Humoral Hypercalcemia of Malignancy Syndrome: a Case Report On Parathyroid Hormone-related Protein-producing Cholangiocarcinoma." Internal Medicine (Tokyo, Japan), vol. 55, no. 23, 2016, pp. 3453-3457.
Ashihara N, Nakajima K, Nakamura Y, et al. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma. Intern Med. 2016;55(23):3453-3457.
Ashihara, N., Nakajima, K., Nakamura, Y., Kobayashi, M., Shirahata, K., Maeda, C., Uehara, T., Gomi, D., & Ito, N. (2016). Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma. Internal Medicine (Tokyo, Japan), 55(23), 3453-3457.
Ashihara N, et al. Denosumab Is Effective for Controlling Serum Calcium Levels in Patients With Humoral Hypercalcemia of Malignancy Syndrome: a Case Report On Parathyroid Hormone-related Protein-producing Cholangiocarcinoma. Intern Med. 2016;55(23):3453-3457. PubMed PMID: 27904108.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma. AU - Ashihara,Norihiro, AU - Nakajima,Koji, AU - Nakamura,Yoshiyuki, AU - Kobayashi,Mutsuhiro, AU - Shirahata,Kumiko, AU - Maeda,Chika, AU - Uehara,Takeshi, AU - Gomi,Daisuke, AU - Ito,Nobuo, Y1 - 2016/12/01/ PY - 2016/12/2/entrez PY - 2016/12/3/pubmed PY - 2017/2/7/medline SP - 3453 EP - 3457 JF - Internal medicine (Tokyo, Japan) JO - Intern Med VL - 55 IS - 23 N2 - Hypercalcemia resulting in the elevation of serum parathyroid hormone-related protein (PTHrP) and suppression of serum PTH was observed in a patient with advanced cholangiocarcinoma (CCC) and multiple lymph node metastases. We confirmed humoral hypercalcemia of malignancy based on PTHrP-producing CCC. Chemotherapy with gemcitabine and cisplatin could not control the patient's serum PTHrP levels and the patient was affected with bisphosphonate-refractory hypercalcemia. We administered a single dose of denosumab, an anti-receptor activator of nuclear factor-kappaB ligand monoclonal antibody, and the patient's serum calcium levels remained close to the normal range for approximately 3 weeks without additional treatment. SN - 1349-7235 UR - https://www.unboundmedicine.com/medline/citation/27904108/Denosumab_is_Effective_for_Controlling_Serum_Calcium_Levels_in_Patients_with_Humoral_Hypercalcemia_of_Malignancy_Syndrome:_A_Case_Report_on_Parathyroid_Hormone_related_Protein_producing_Cholangiocarcinoma_ DB - PRIME DP - Unbound Medicine ER -